Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max - PubMed (original) (raw)
. 1992 Oct 1;359(6394):423-6.
doi: 10.1038/359423a0.
Affiliations
- PMID: 1406955
- DOI: 10.1038/359423a0
Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max
B Amati et al. Nature. 1992.
Abstract
The c-myc protein (Myc) contains an amino-terminal transcriptional activation domain and a carboxy-terminal basic helix-loop-helix-leucine zipper (bHLH-Z) domain that directs dimerization of Myc with its partner, the max protein (Max), and promotes DNA binding to sites containing a CACGTG core consensus sequence. Despite these characteristics and the observation that Myc can modulate gene expression, a direct role for Myc or Max as transcription factors has never been demonstrated. Here we use Saccharomyces cerevisiae as an in vivo model system to show that the Myc protein is a sequence-specific transcriptional activator whose DNA binding is strictly dependent on dimerization with Max. Transactivation is mediated by the amino-terminal domain of Myc. We find that Max homodimers bind to the same DNA sequence as Myc+Max but that they fail to transactivate and thus can antagonize Myc+Max function. We also show that the Max HLH-Z domain has a higher affinity for the Myc HLH-Z domain than for itself, and suggest that the heterodimeric Myc+Max activator forms preferentially at equilibrium.
Similar articles
- Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
Västrik I, Mäkelä TP, Koskinen PJ, Alitalo K. Västrik I, et al. Oncogene. 1995 Aug 3;11(3):553-60. Oncogene. 1995. PMID: 7630640 - The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B, Larsson LG. Lüscher B, et al. Oncogene. 1999 May 13;18(19):2955-66. doi: 10.1038/sj.onc.1202750. Oncogene. 1999. PMID: 10378692 Review. - myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
Västrik I, Mäkelä TP, Koskinen PJ, Saksela K, Alitalo K. Västrik I, et al. Princess Takamatsu Symp. 1991;22:307-18. Princess Takamatsu Symp. 1991. PMID: 1668890 Review.
Cited by
- MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. Casacuberta-Serra S, et al. Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z. Signal Transduct Target Ther. 2024. PMID: 39164274 Free PMC article. Review. - Manipulating Myc for reparative regeneration.
Ascanelli C, Dahir R, Wilson CH. Ascanelli C, et al. Front Cell Dev Biol. 2024 Mar 21;12:1357589. doi: 10.3389/fcell.2024.1357589. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38577503 Free PMC article. Review. - MYC: there is more to it than cancer.
Zacarías-Fluck MF, Soucek L, Whitfield JR. Zacarías-Fluck MF, et al. Front Cell Dev Biol. 2024 Mar 6;12:1342872. doi: 10.3389/fcell.2024.1342872. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38510176 Free PMC article. Review. - MYC function and regulation in physiological perspective.
Jha RK, Kouzine F, Levens D. Jha RK, et al. Front Cell Dev Biol. 2023 Oct 24;11:1268275. doi: 10.3389/fcell.2023.1268275. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37941901 Free PMC article. Review. - MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival.
Hurd M, Pino J, Jang K, Allevato MM, Vorontchikhina M, Ichikawa W, Zhao Y, Gates R, Villalpando E, Hamilton MJ, Faiola F, Pan S, Qi Y, Hung YW, Girke T, Ann D, Seewaldt V, Martinez E. Hurd M, et al. Genes Dev. 2023 Oct 1;37(19-20):865-882. doi: 10.1101/gad.350736.123. Epub 2023 Oct 18. Genes Dev. 2023. PMID: 37852796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources